The Drugs Controller General of India (DCGI) has approved Bharat Biotech’s Covaxin to conduct the Phase 2-3 clinical trials on children aged 2-18 years. Bharat Biotech will conduct the clinical trials on 525 healthy volunteers in the below 18 age group. Watch the video for more information.
Be the first to comment